Who's who

3 Houston innovators to know this week

From oil and gas to space technology, these leaders are pushing forward innovation in Houston. Courtesy photos

One thing this week's movers and shakers in the Houston innovation ecosystem have in common is their intention to disrupt an industry using technology. Here are this week's innovators you need to know in Houston.

Francois Laborie, general manager of Cognite North Americas

Courtesy of Cognite

When it comes to data, most energy companies are squandering valuable information by not properly using their data. Cognite, which has its US headquarters in Texas, has solutions, says general manager of the company, Francois Laborie.

"Standardizing APIs across the oil and gas industry would open the door to a community of developers, which could create custom applications and connect existing market solutions," he writes in a guest column for InnovationMap. "Then more new and exciting applications and services would reach the market faster."

Click here to read Laborie's article on the importance of APIs and data management.

Steven Gonzalez, technology transfer strategist at NASA

Courtesy of NASA

Houston is the Space City — present tense. While the city has a rich history as a major player in aerospace exploration and engineering, Houston is far from done, Steven Gonzales, NASA technology transfer strategist, tells InnovationMap.

We've always been the Space City, but for a while there, it was taken for granted. It's part of our history, but it's nice to see it brought back into the foreground to realize that it's not just history, it's who we are today.

Click here to read our Space City Month feature on Gonzalez in which he explains Houston's future in space and how NASA wants to work with startups.

Christine Galib, program director of The Ion Smart Cities Accelerator

Courtesy of Station Houston

Christine Galib has a new gig in town. The former Rice University and St. Thomas University educator is now the program director of the Ion Smart Cities Accelerator, a program that will find and grow startups with solutions to Houston's biggest problems.

"When we look at The Ion being created as a center for entrepreneurship and innovation in Houston, there's no other city in the world has this type of level of collaboration and transparency of major players in the innovation space coming together to create, not only the physical space, but also the programming and mindset and the environment and the culture to sustain it," she tells InnovationMap.

Click here to read more about Galib and what she's excited to bring to town.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News